Ajanta Pharma has entered an in-licensing agreement with Biocon for Semaglutide, a GLP-1 receptor agonist. Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East, and Central Asia. Ajanta plans to commercialize after regulatory approvals, expected in late 2026 or early 2027.
Semaglutide Agreement Details
Ajanta Pharma Ltd. has announced an in-licensing agreement with Biocon Ltd. for Semaglutide, a GLP-1 receptor agonist. This agreement, announced on December 23, 2025, enables Ajanta to expand its portfolio and market presence in several key regions.
Market Expansion Plans
Under this agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East, and Central Asia. This strategic move will allow Ajanta Pharma to broaden its reach and impact in these regions. Ajanta plans to commercialize the products after receiving the necessary regulatory approvals, which are expected in late 2026 or early 2027.
Strategic Rationale
Semaglutide is designed to improve glycaemic control in adults. Ajanta Pharma has been building a branded generic business across Africa, South-East Asia, Central Asia, and the Middle East with a wide range of therapeutic segments. According to Yogesh Agrawal, Managing Director of Ajanta Pharma Ltd., Ajanta is excited to partner with Biocon and confident of building Semaglutide into a meaningful and high-growth brand across these countries.
Biocon’s Perspective
Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Ltd., stated that this partnership with Ajanta Pharma is a strategic step in expanding the global footprint of Biocon’s GLP-1 portfolio and maximizing the value of scientific investments. This collaboration will enable broader and more affordable access to Semaglutide for patients in these regions.
Ajanta’s Financials
For the FY 2024-25, Ajanta has posted Revenue of Rs. 4,648 cr., EBIDTA of Rs. 1,260 cr. (27%) and PAT of Rs. 920 cr. (20%). For the last 3 financial years, Ajanta has posted healthy revenue CAGR of 11% and even stronger PAT CAGR of 25%.
Source: BSE